Cilengitide EMD 121974

Phase 2Small molecule

BBart Neyns

Cilengitide EMD 121974 is one of 17 small molecule programs targeting Overall Survival. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Overall SurvivalActive, not recruiting

Overall SurvivalPhase 2

Active, not recruiting

Competition

Competitive Landscape

18 competitors in Overall Survival

#DrugCompanyPhaseTrials

Camptosar

Eloxatin

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Brukinsa

Opdivo

1 6

Vectibix

Amgen

Phase 2

1 7

Gemzar

Johnson & Johnson

Phase 2

1 8

Rituxan

Erbitux

1 10

Ibrance

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Overall Survival1 trial

Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma

Terminated·BBart Neyns·Phase 2·NCT01044225·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cilengitide EMD 121974. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cilengitide EMD 121974 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cilengitide EMD 121974. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bart Neyns company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBart Neyns

Cilengitide EMD 121974

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Overall Survival1 trial

References

Drug Info

Quick Facts

Related News